Regado Biosciences Inc. (NASDAQ:RGDO) took a pretty steep haircut to get out the door last month but buysiders say the issues were company-specific and not a sign that appetite for IPOs is waning among public investors.

The sentiment is welcome news for the 17 biotechs still in the IPO queue but could leave Regado short on funds.